Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

AstraZeneca : Imfinzi fails to meet main goals in head and neck cancer study

share with twitter share with LinkedIn share with facebook
share via e-mail
12/07/2018 | 08:55am CET
A sign is seen at an AstraZeneca site in Macclesfield

(Reuters) - AstraZeneca Plc immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday.

The study, known as "EAGLE", did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease, the company said.

The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.

AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.

"While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer," said Chief Medical Officer Sean Bohen.

The trial was conducted at 169 centres across 24 countries including the U.S., Europe, South America, Japan, Korea, Taiwan, Israel and Australia, AstraZeneca said.

(Reporting by Sangameswaran S and Noor Zainab Hussain in Bengaluru; Editing by Sai Sachin Ravikumar, Bernard Orr)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
12/10EUROPE MARKETS: European Stocks End Sharply Lower As Data Add To Worries Abou..
12/10LONDON MARKETS: FTSE 100 Dragged Lower As U.K.'s May Delays Brexit Vote
12/10Imfinzi-tremelimumab combo fails Phase III for head and neck cancer
12/10ASTRAZENECA : and Cancer Research UK launch Functional Genomics Centre to accele..
12/08Moderna Declines in Market Debut -- WSJ
12/07Moderna Declines in Public-Market Debut
12/07Moderna sets IPO record with upsized $604M offering
12/07ASTRAZENECA : Imfinzi fails to meet main goals in head and neck cancer study
12/07ASTRAZENECA : Results From Imfinzi Head and Neck Cancer Trial Negative
12/07ASTRAZENECA : Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in..
More news
News from SeekingAlpha
12/10Ligand Pharma up 1% on advancement of lasofoxifene by licensee Sermonix 
12/07AstraZeneca's Imfinzi fails to extend survival over chemo in late-stage HNSCC.. 
12/06CLOVIS ONCOLOGY : Outlook Post-Tesaro Acquisition 
12/06THW : Global Healthcare Fund With 10%+ Yield 
12/06Puma Bio's neratinib + fulvestrant showed positive effect in mid-stage breast.. 
Financials ($)
Sales 2018 22 124 M
EBIT 2018 5 621 M
Net income 2018 2 403 M
Debt 2018 14 894 M
Yield 2018 3,59%
P/E ratio 2018 39,64
P/E ratio 2019 33,46
EV / Sales 2018 5,05x
EV / Sales 2019 4,74x
Capitalization 96 842 M
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,3 $
Spread / Average Target 6,4%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA17.30%96 842
JOHNSON & JOHNSON3.97%390 040
PFIZER21.26%254 736
NOVARTIS5.58%223 559
ROCHE HOLDING LTD.1.70%217 483
MERCK AND COMPANY37.59%199 501